Posts Tagged ‘business’


In STEM CELLS IN THE NEWS on April 5, 2012 at 4:46 am

This article which can be found at http://www.scribd.com/doc/79116123/New-Scientist-November-19th-2011 (page 14) references embryonic like stem cells in breast milk as the first ever found in adults. This is incorrect. Embryonic like stem cells or stem cells with totipotency has been found in a number of other adult stem cells previously. I am referring to naturally occurring adult stem cells as opposed to ipsc.

That said, a concept of FDA regulation of breast feeding is not that far from the truth unfortunately. See my article here: https://repairstemcell.wordpress.com/2012/03/21/fdas-new-claim-your-body-is-a-drug-and-we-have-the-authority-to-regulate-it-the-alliance-for-natural-health-usa/




In SCIENCE & STEM CELLS on October 18, 2011 at 11:06 am
In construction parlance… If the stem cells are the little workers with their little construction belts on ready to fix and repair, don’t they need a Foreman or General Contractor to tell them what to do? Which cells are they? Just Curious. – Ken

good question Ken!

in cell phone parlance:
do you have a smart phone? it is able to do things that the dumb phones can’t. stem cells are smart cells, not dumb cells. they are the best workers ever because they are motivated, self-actualizing, dedicated, intelligent and have no ego.in military parlance:they are marines! throw them into the fiercest battle where the worst damage is and they will adapt, improvise, overcome and leave no organ behind!

in business parlance:

they go where your body is damaged and fix things (repair necrotic or dead tissue and create new tissue). they don’t mind healing the pancreas even if their job description is to fix the heart. they will build tiny capillaries at the site of your shunt where you had plaque build up, angioplasty and a shunt installed even if it is working well (they know it is a high potential risk/breakdown area). these are essentially mini, bypasses and they may create dozens of them at a time. meaning, they fix problem areas and create backup fixes even if it ain’t broke at the moment, cause they are better at it than any surgeon or surgical technique available and they know in time all artificial solutions will fail.

in naval parlance:

they have no self-preservation/survival instinct. they are all captains and think nothing of manning the helm while the ship goes down because they are in it for the good of the entire body and know that their sacrifice may be the difference between the body’s survival or death.

in kitchen/sports parlance:

too many cooks spoil the stew, right? wrong! stem cells are brilliant at working together. they have no egos. they are just as happy dunking the ball OR throwing the ‘alley oop’ OR wiping down the floor after the game. look closely at the words: “stem cell.” do you see it? There is no “I” in stem cell! but there is a ‘T’ an ‘E’ an ‘A’ and an ‘M’!

we don’t yet know how they KNOW how do the things they do, all we know is that it is their job, they are very good at it and they will not rest until the job is done. no defeat, no surrender!

Influential research misses financial conflicts | Reuters

In BUSINESS OF STEM CELLS on March 9, 2011 at 12:40 pm

A pharmacy employee dumps pills into a pill counting machine as she fills a prescription while working at a pharmacy in New York December 23, 2009. REUTERS/Lucas Jackson

By Frederik Joelving

NEW YORK | Wed Mar 9, 2011 1:51am EST

NEW YORK (Reuters Health) – Scientists who review large sets of drug trials for medical journals often ignore financial conflicts that might warp the evidence, according to a study out Tuesday.

That’s more than just an academic problem, experts say, because the reviews are considered just about the strongest evidence that medical science can muster.

“It influences how physicians make decisions and how guideline panels come up with their guidelines,” said Brett D. Thombs, of McGill University and the Jewish General Hospital in Montreal, whose findings are published in the Journal of the American Medical Association (JAMA).

Thombs’ team found that of 29 reviews, or “meta-analyses,” of earlier drug trials — culled from top journals like JAMA and The Lancet — only two reported who had funded the original trials included in the review.

And none of the reviews mentioned whether the authors reporting on those trials had been paid by drugmakers.

Such financial ties have been linked to research inflating the benefits of new drugs and downplaying the risks, said Thombs.


Influential research misses financial conflicts | Reuters.

Big Pharma Scores Big Win: Medicinal Herbs Will Disappear in EU

In BUSINESS OF STEM CELLS on September 24, 2010 at 1:31 am

Big Pharma Scores Big Win: Medicinal Herbs Will Disappear in EU

It’s almost a done deal. We are about to see herbal preparations disappear, and the ability of herbalists to prescribe them will also be lost.

by Heidi Stevenson – 12 September 2010

Big Pharma has almost reached the finish line of its decades-long battle to wipe out all competition. As of 1 April 2011—less than eight months from now—virtually all medicinal herbs will become illegal in the European Union. The approach in the United States is a bit different, but it’s having the same devastating effect. The people have become nothing more than sinks for whatever swill Big Pharma and Agribusiness choose to send our way, and we have no option but to pay whatever rates they want.

Big Pharma and Agribusiness have almost completed their march to take over every aspect of health, from the food we eat to the way we care for ourselves when we’re ill. Have no doubt about it: this takeover will steal what health remains to us…

via Big Pharma Scores Big Win: Medicinal Herbs Will Disappear in EU.


In BUSINESS OF STEM CELLS on August 25, 2009 at 9:49 pm

HARD TO TREAT DISEASES (PINK:HTDS) is trading up 5% at $0.0103 on huge volume of 87 million shares. Yesterday, 24 August, Hard to Treat Diseases (HTDS.PK) Dr. Sanja Pekovic, Chief Project Scientist, Chief Strategy Officer Slavica BioChem reported that IBISS research group from Serbia has begun preliminary experiments within a project aimed at Promoting stem cell graft survival in the model of traumatic brain injury in rats. One of the goals of this project is to examine the potential role of Ribavirin in promoting survival of the stem cells transplanted after brain injury.

via SYMPOWERCO CORP (PINK:SYMW) Is The Top Traded OTC Stock.

Stem cell firm plans Russia’s 1st post-crisis IPO | Stocks | Reuters

In BUSINESS OF STEM CELLS on August 25, 2009 at 9:44 pm

MOSCOW (Reuters) – Russia’s Stem Cell Institute is seeking to attract some 150 million roubles ($4.75 million) from investors in what would be the country’s first initial public offering in more than a year, the firm’s head said on Tuesday.

The news comes as Russia’s economy is showing early signs of starting to recovering from recession while some of its larger companies again begin to attract funding on domestic and international markets.

The Stem Cell Institute, which has been valued at 500 million roubles, plans to place 25 percent of its capital in mid-November on the innovation and developing companies sector of Russia’s MICEX exchange.

via Stem cell firm plans Russia’s 1st post-crisis IPO | Stocks | Reuters.

Stem Cell Innovation At Risk In UK, Studies Find

In ALL ARTICLES, BUSINESS OF STEM CELLS on April 6, 2009 at 12:42 pm


ScienceDaily (Apr. 6, 2009) — Despite great hopes for stem cell therapy, major structural and cultural changes within the National Health Service (NHS) are needed if it is to succeed in the UK. Currently the chances of getting effective treatments into routine use in the short-term are small and the industry is at serious risk of ‘market failure’.

These are the findings of two major studies into the commercialisation and adoption of stem cell therapy carried out by researchers at The University of Nottingham.

Dr Paul Martin, from the Institute of Science and Society said: “While the government has identified regenerative medicine as a national priority and the US has lifted its ban on stem cell therapy, urgent public policy action is needed if it is to become a reality. Although cell therapy is now established as an important branch of medicine, innovative firms struggle to make money, putting the UK industry in a very vulnerable position in the short term. Unless the situation changes the industry will contract and the progress needed to develop important cell therapies will be adversely affected.”

via Stem Cell Innovation At Risk In UK, Studies Find.

Amniotic Fluid May Provide New Source of Stem Cells for Future Therapies – FOXBusiness.com

In ALL ARTICLES, STEM CELLS IN THE NEWS on April 1, 2009 at 5:26 am


Tuesday, March 31, 2009

WASHINGTON, March 31, 2009 /PRNewswire-USNewswire via COMTEX/ —-For the first time, scientists have shown that amniotic fluid (the protective liquid surrounding an embryo) may be a potential new source of stem cells for therapeutic applications. The study was prepublished online on February 12, 2009, in Blood, the official journal of the American Society of Hematology.

“Building on observations made by other scientists, our research team wondered whether stem cells could be detected in amniotic fluid. We looked at the capacity of these cells to form new blood cells both inside and outside the body, and also compared their characteristics to other well-known sources of stem cells,” said senior study author Marina Cavazzana-Calvo, MD, Ph.D., of INSERM, the national French institute for health and biomedical research. Isabelle Andre-Schmutz, Ph.D., of INSERM, also a senior author of the study, added, “The answer was a resounding ‘yes’ – the cells we isolated from the amniotic fluid are a new source of stem cells that may potentially be used to treat a variety of human diseases.”

via Amniotic Fluid May Provide New Source of Stem Cells for Future Therapies – FOXBusiness.com.

%d bloggers like this: